Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:07 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive Lung, Colorectal, or Pancreatic Cancer
NCT04870034 · Roswell Park Cancer Institute · EARLY_PHASE1 · withdrawn · last registry update 2023-12-22 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Issues recruiting” | Open Targets' class: insufficient enrollment | Registry record, Roswell Park Cancer Institute |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAP2K1 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-09-19Also stopped (terminated): Taiho Oncology, Inc., Futibatinib and Binimetinib (NCT04965818)
- 2024-06-11Also stopped (terminated): Collin Blakely, Capmatinib + Trametinib (NCT05435846)
- 2023-10-30Results posted on the registry: Pfizer, encorafenib + binimetinib (NCT03915951)
- 2023-09-21Results posted on the registry: Memorial Sloan Kettering Cancer Center, Trametinib 0.5 mg + Trametinib 1 MG (NCT03704688)
- 2023-06-22Results posted on the registry: Pfizer, Sasanlimab Prefilled syringe + Encorafenib (NCT04585815)
- 2023-04-11Results posted on the registry: National Cancer Institute (NCI), AZD6244 + MK-2206 (NCT01306045)
- 2023-03-14Phase 3 first posted: Cancer Research UK, Vemurafenib + Cobimetinib (NCT05768178)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision